SOS-AMI (NCT04957719)
Selatogrel Outcome Study in Suspected Acute Myocardial Infarction (SOS-AMI)
Multi-center, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of self-administered subcutaneous selatogrel for prevention of all-cause death and treatment of acute myocardial infarction in subjects with a recent history of acute myocardial infarction.
Brief Summary:
This study will randomize patients recently discharged from the hospital with a confirmed diagnosis of type 1 acute myocardial infarction and having additional cardiovascular risk factors.
Detailed Description:
The purpose of this study is to assess the clinical efficacy of selatogrel when self-administered upon occurrence of symptoms suggestive of an acute myocardial infarction (AMI) in participants at risk of having a recurrent AMI.
ACTIVE ENROLLING SIGN UP
SPONSOR: Idorsia Pharmaceuticals, Ltd
Eligibility Requirements
1. Male or female subject ≥ 18 years old
2. Discharged with a confirmed diagnosis of symptomatic type 1 AMI (STEMI or NSTEMI), no longer than 4 weeks prior to randomization
